These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38626513)

  • 1. Unresectable biliary tract cancer: Current and future systemic therapy.
    Zhang D; Dorman K; Westphalen CB; Haas M; Ormanns S; Neumann J; Seidensticker M; Ricke J; De Toni EN; Klauschen F; Algül H; Reisländer T; Boeck S; Heinemann V
    Eur J Cancer; 2024 May; 203():114046. PubMed ID: 38626513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C; McGrath NA; Monge Bonilla C; Fu J
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
    Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
    ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.
    Yue S; Zhang Y; Zhang W
    Curr Treat Options Oncol; 2024 Aug; 25(8):1089-1111. PubMed ID: 39066855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 6. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
    Hack SP; Zhu AX
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
    Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
    Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
    Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
    Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of novel biologics in biliary cancers.
    Jordan E; Braghiroli MF; Lowery MA
    Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 12. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in advanced biliary malignancies: a clinical review.
    Grewal US; Gaddam SJ; Beg MS; Brown TJ
    Expert Rev Anticancer Ther; 2024 Sep; 24(9):869-880. PubMed ID: 39083012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapies in clinical development for biliary tract cancer.
    Vogel A; Bathon M; Saborowski A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):351-363. PubMed ID: 33382361
    [No Abstract]   [Full Text] [Related]  

  • 15. Biliary tract carcinomas: from chemotherapy to targeted therapy.
    Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward personalized treatment of advanced biliary tract cancers.
    Geynisman DM; Catenacci DV
    Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
    Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
    Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 20. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
    Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
    Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.